×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma

Silas Inman
Calquence (acalabrutinib) was granted an accelerated approval by the FDA to treat adult patients with mantle cell lymphoma (MCL) following at least one prior therapy. The approval was based on objective response rates (ORR) in a single-arm trial.
Ryan Hamner
Cobra, baseball cards and two guys who always let me know I wasn't dead.
Beth Incollingo
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.
Jason Harris
Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma
Jason M. Broderick
Aliqopa (copanlisib) was granted FDA approval for the treatment of patients with relapsed follicular lymphoma who have received at least two least prior systemic therapies.
Jason Harris
The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.
 
Jason Harris
A type of CAR-T cell therapy is showing promise in a phase 1 study for patients with Hodgkin lymphoma and ALCL.
Adriana Lecuona
Theresa Sullivan Barger
To prevent family conflicts over cancer treatment decisions, experts recommend a series of frank conversations.
Jason Harris
Acalabrutinib was granted a priority review to a new drug application (NDA) to be used to treat patients with mantle cell lymphoma (MCL) who have had previous treatment, according to AstraZeneca, the manufacturer of the drug.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable